Nektar Therapeutics expects cash runway into at least mid 2026

Nektar Therapeutics ( NASDAQ: NKTR ) had cash and cash equivalents of $329M as of December 31, 2023 based on preliminary estimates, as per a recent filing . This should provide the company with cash runway into at least the middle of 2026. Key upcoming milestones for the biopharma company include: initiation of REZPEG Phase 2b study in alopecia areata in the first quarter of 2024, interim results of NKTR 255 from the JAVELIN Bladder Medley Study expected in second half of 2024 and investigational new drug enabling studies for NKTR 0165 in fourth quarter.

Shares of Nektar Therapeutics ( NKTR ) fell as much as 8% premarket on Thursday More on Nektar Therapeutics Nektar Therapeutics (NKTR) Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Nektar Therapeutics Historical earnings data for Nektar Therapeutics Financial information for Nektar Therapeutics.